
|Videos|October 25, 2013
Ovarian Cancer Maintenance Therapy With Bevacizumab
Author(s)Robert A. Burger, MD
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
Advertisement
Clinical Pearls
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
- In frontline trials, bevacizumab was administered with a maximum number of treatment cycles beyond chemotherapy
- In second-line trials, maintenance therapy was continued until disease progression
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5








































